The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...

If you or someone you love has heart failure and unresolved, seemingly unrelated symptoms such as carpal tunnel syndrome, shortness of breath, irregular heartbeat, or even lower back pain, it could be ...

The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital. Results for the ...

The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...

Correspondence to Dr W. H. Wilson Tang, Department of Cardiovascular Medicine, Heart and Vascular Institute9500 Euclid Avenue, Desk J3-4, Cleveland, Ohio 44195; tangw{at}ccf.org Given increased ...

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

The disorder most frequently affects the heart, kidneys, gastrointestinal tract, and nervous system. Other common sites of amyloid accumulation include the tongue, skeletal and smooth muscles ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...